NOMINATION: eGenesis appoints Daniel Leblanc as Chief Manufacturing and Supply Officer

The significance of Daniel Leblanc's appointment is the concentration of manufacturing, quality and supply accountability as eGenesis prepares for clinical and potential commercial scale-up. The important decision is not simply who leads these functions, but how authority is divided when manufacturing capacity, quality requirements, external supply commitments and supply planning priorities conflict. The appointment can strengthen coordination if decision rights are explicit: manufacturing must own executable capacity assumptions, quality must retain authority over release and compliance requirements, external supply commitments must be visible, and cross-functional trade-offs must have a clearly accountable executive owner. The main failure mode is concentrated responsibility without an effective decision model, leaving critical capacity, quality and supply trade-offs unresolved or escalated too late. The appointment is confirmed; improvements in operating performance, supply reliability or commercialization readiness remain to be demonstrated.